The consideration for the timing of vector administration should be carefully balanced between the desire to treat patients in late childhood or adulthood to achieve persistently high levels of OAT expression and earlier treatment to pre‐empt the onset of retinal degeneration. This evidence concerns the gene OAT and retinal degeneration.